Delivra Signs Technology Licensing Agreement With Kalytera Therapeutics

TORONTO, ON--(Marketwired - June 02, 2016) - Delivra Corp. ("Delivra" or the "Company") (TSX VENTURE: DVA) is pleased to announce it has entered into a technology licensing agreement (the "License") with Kalytera Therapeutics, Inc. ("Kalytera").

Based in California, Kalytera is a pharmaceutical company developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that it believes will address large unmet market needs. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone health.

"Synthetic and natural cannabinoid therapies are an expanding field of medicine with significant potential. This agreement provides an opportunity for Delivra to pair our leading transdermal technologies with Kalytera and its partners, who have a proven track record in pioneering synthetic cannabinoid compounds to address a range of pervasive conditions," said Chris Schnarr, President of Delivra. "We believe our delivery platform provides a strong value proposition both for existing and new active pharmaceutical ingredients and anticipate that this transaction will be one in a series of deals that showcase the breadth and value of the Delivra technology."

Under the terms of the License, Delivra will license its proprietary transdermal delivery technology to Kalytera for its exclusive use with two synthetic cannabinoid compounds which Kalytera has under license (KAL436/439 and KAL671) and only for use with respect to specific indications which include bone healing, osteogenesis imperfecta, and osteoporosis. The licensed territory is worldwide, but excludes Canada. During the term of the license, Kalytera is required to make various milestone payments to Delivra through a combination of cash and Kalytera stock, immediately and then as and when it progresses through the US FDA drug approval process over the next several years, followed by a royalty to Delivra on resulting product sales once an approved drug is on the market.

In addition, Kalytera may also take up a non-exclusive license for the use of Delivra technology for transdermal delivery of cannabis plant extracts or isolated active ingredients from the cannabis plant, for the specific indications noted above, in non-FDA regulated markets. This license is non-exclusive worldwide, and excludes Canada. This license would include an immediate cash payment upon exercise as well as a further milestone payment on the first commercial sale of a resulting product, followed by a royalty to Delivra on resulting product sales once an approved drug is on the market.

"Many oral medications degrade during passage through the gastrointestinal tract," said Dr. Stuart Silverman, M.D., FACP, FACR, Co-Chair of Kalytera's Scientific Advisory Board . "This may effect efficacy or it may cause other unwanted side effects. We were attracted to Delivra's technologies which have demonstrated the ability to reliably deliver molecules through the skin, with desirable pharmacokinetics."

"In concert with the research now underway at Hebrew University and Tel Aviv University, securing a delivery platform and partner is an important step in advancing Kalytera's drug candidates towards the clinic," said Dr. Raphael Mechoulam, Ph.D., Co-Chair of Kalytera's Scientific Advisory Board.

If all milestones are met, the total cash and stock payments would be approximately USD $1.4 million. The royalty percentage is not being disclosed, for commercial and competitive reasons. Unless terminated earlier, the License has a term of ten (10) years and is subject to optional additional two (2) year renewal terms. There can be no guarantees that the milestones in the License will be met or that any milestone payments or royalty payments will be made.

ABOUT KALYTERA, INC.

Kalytera Therapeutics is developing a portfolio of non-psychoactive cannabinoid and endocannabinoid-like medicines that it believes will address large unmet market needs. Kalytera seeks to commercialize its proprietary synthetic cannabinoid therapies across a range of disease states, with an initial focus on bone health.

For more information, visit: http://kalytera.co.

ABOUT DELIVRA CORP.

Delivra Corp. is a developer of transdermal technologies for the delivery of pharmaceutical and natural molecules through the skin, rather than via pills. Delivra manufactures and sells a growing line of natural topical creams under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. In parallel with its consumer products business, Delivra also has a mandate to license its unique, proven, and patent-pending delivery platform to global pharmaceutical companies for the transdermal delivery of third party active ingredients to treat a broad range of conditions. With a global transdermal drug delivery market forecast to grow to USD $40 billion by 2018 (Source: Kelly Scientific), Delivra believes the licensing opportunity is robust. Delivra is headquartered in Burlington, Ontario, Canada and has a research and development laboratory in Charlottetown, PEI, Canada.

Further information on the Company can be found at www.delivracorp.com and www.livrelief.com.

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Factors that might cause actual results to differ include obtaining the Company or its partners and licensees obtaining necessary regulatory approvals in a timely fashion, changes in the business conditions and direction of the Company's partners and licensees, the effectiveness of the Company's technology with particular molecules or compounds for particular indications, the availability of alternate and competitive transdermal delivery systems, protection and further development of the Company's intellectual property and related future products, availability of additional financings, changes in currency exchange rates, retaining key personnel, competitive conditions and acceptance of the Company's products by consumers in key markets. Additional information identifying risks and  uncertainties is contained in the Corporation's filings with the Canadian securities regulators, which filings are available at www.sedar.com.